Findlay Park Partners LLP Sells 101,525 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

Findlay Park Partners LLP lessened its holdings in UnitedHealth Group Incorporated (NYSE:UNH – Get Rating) by 33.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 199,669 shares of the healthcare conglomerate’s stock after selling 101,525 shares during the quarter. Findlay Park Partners LLP’s holdings in UnitedHealth Group were worth $105,861,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of UNH. O Dell Group LLC lifted its position in UnitedHealth Group by 76.9% during the third quarter. O Dell Group LLC now owns 69 shares of the healthcare conglomerate’s stock worth $35,000 after purchasing an additional 30 shares during the period. Legend Financial Advisors Inc. acquired a new position in UnitedHealth Group during the third quarter worth about $37,000. Investors Research Corp raised its stake in UnitedHealth Group by 51.1% during the fourth quarter. Investors Research Corp now owns 71 shares of the healthcare conglomerate’s stock worth $38,000 after acquiring an additional 24 shares in the last quarter. Bourgeon Capital Management LLC raised its stake in UnitedHealth Group by 192.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 76 shares of the healthcare conglomerate’s stock worth $40,000 after acquiring an additional 50 shares in the last quarter. Finally, WFA of San Diego LLC acquired a new position in shares of UnitedHealth Group in the fourth quarter valued at approximately $42,000. Institutional investors own 86.31% of the company’s stock.

UnitedHealth Group Price Performance

Shares of NYSE:UNH opened at $479.44 on Wednesday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 0.71. The stock’s fifty day simple moving average is $489.26 and its two-hundred day simple moving average is $500.06. UnitedHealth Group Incorporated has a 1-year low of $449.70 and a 1-year high of $558.10. The stock has a market cap of $446.37 billion, a PE ratio of 21.92, a price-to-earnings-growth ratio of 1.39 and a beta of 0.68.

UnitedHealth Group (NYSE:UNH – Get Rating) last issued its quarterly earnings data on Friday, April 14th. The healthcare conglomerate reported $6.26 earnings per share for the quarter, beating the consensus estimate of $6.24 by $0.02. UnitedHealth Group had a return on equity of 27.05% and a net margin of 6.16%. The business had revenue of $91.93 billion for the quarter, compared to analysts’ expectations of $89.77 billion. During the same period last year, the business earned $5.49 EPS. The business’s revenue was up 14.7% on a year-over-year basis. As a group, analysts forecast that UnitedHealth Group Incorporated will post 24.98 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 21st. Investors of record on Monday, March 13th were issued a $1.65 dividend. This represents a $6.60 annualized dividend and a yield of 1.38%. The ex-dividend date of this dividend was Friday, March 10th. UnitedHealth Group’s dividend payout ratio (DPR) is currently 30.18%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on UNH. Oppenheimer reaffirmed an “outperform” rating and issued a $610.00 price objective on shares of UnitedHealth Group in a research note on Monday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $592.00 target price on shares of UnitedHealth Group in a research report on Monday, April 17th. TD Cowen decreased their target price on shares of UnitedHealth Group from $596.00 to $562.00 and set an “outperform” rating for the company in a research report on Monday, April 17th. Raymond James reissued a “strong-buy” rating and set a $630.00 target price on shares of UnitedHealth Group in a research report on Friday, April 14th. Finally, StockNews.com began coverage on shares of UnitedHealth Group in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, UnitedHealth Group presently has a consensus rating of “Buy” and an average target price of $600.88.

Insider Buying and Selling

In related news, EVP Erin Mcsweeney sold 1,008 shares of UnitedHealth Group stock in a transaction dated Friday, April 21st. The stock was sold at an average price of $484.58, for a total value of $488,456.64. Following the completion of the sale, the executive vice president now owns 10,359 shares of the company’s stock, valued at approximately $5,019,764.22. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other UnitedHealth Group news, EVP Erin Mcsweeney sold 1,008 shares of the firm’s stock in a transaction dated Friday, April 21st. The stock was sold at an average price of $484.58, for a total value of $488,456.64. Following the completion of the transaction, the executive vice president now owns 10,359 shares in the company, valued at approximately $5,019,764.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Witty sold 6,160 shares of the firm’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $487.49, for a total value of $3,002,938.40. Following the completion of the transaction, the chief executive officer now owns 86,564 shares of the company’s stock, valued at approximately $42,199,084.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,852 shares of company stock valued at $4,313,962. 0.35% of the stock is owned by insiders.

UnitedHealth Group Profile

(Get Rating)

UnitedHealth Group, Inc engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum’s capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience.